<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03235063</url>
  </required_header>
  <id_info>
    <org_study_id>Prog/10/17</org_study_id>
    <nct_id>NCT03235063</nct_id>
  </id_info>
  <brief_title>Pregnancy and Dilated Cardiomyopathy</brief_title>
  <official_title>Registry of Pregnancy Follow-up in Patients With Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing cases of women with dilated cardiomyopathy with a project of pregnancy are&#xD;
      observed. However there is few knowledge and publications about cardiac diseases in pregnant&#xD;
      women. Moreover the majority of medical articles deal with women with congenital heart&#xD;
      diseases, valvular pathologies or peripartum cardiomyopathies, and few data are available in&#xD;
      literature about women with dilated cardiomyopathy diagnosed before or during the first&#xD;
      months of the pregnancy.&#xD;
&#xD;
      Cardiologist and obstetrician advices are considerably limited when patients with dilated&#xD;
      cardiomyopathy have a pregnancy project. Knowledges and know-how are currently based on&#xD;
      limited personal experiment or on few clinical cases descriptions.&#xD;
&#xD;
      Pregnancy represents a high-risk situation for patients with dilated cardiomyopathy. Creation&#xD;
      of a cohort of pregnant women with dilated cardiomyopathy collecting specific data will allow&#xD;
      to have a better overview and to appreciate possibilities of a pregnancy project, evolution&#xD;
      risks and modalities for medical attention and to improve follow-up and advices delivered to&#xD;
      these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a national (20 centres) retrospective (10 years) and prospective registry of&#xD;
      pregnant women with dilated cardiomyopathy.&#xD;
&#xD;
      As this study is observational, medical attention of the enrolled patients will not be&#xD;
      modified. No specific visit is planned for the study.&#xD;
&#xD;
      Before the enrolment of the patient, the investigator provides the subject with clear and&#xD;
      precise information about the protocol and requests her for written informed consent. The&#xD;
      French ethical committee gave the investigators the possibility to include women in the&#xD;
      registry if the investigators are unable to inform her (deceased women, no follow-up).&#xD;
&#xD;
      The main objective of the study is to evaluate clinical characteristics and study maternal&#xD;
      and neonatal evolution and complications during pregnancy using analysis of the&#xD;
      morbi-mortality and clinical and para clinical criteria.&#xD;
&#xD;
      The following data will be compiled in a case report form (e-CRF):&#xD;
&#xD;
        -  Risk factors, cardiac history&#xD;
&#xD;
        -  BNP or NTproBNP value, echocardiographic data (LVEF and LV diameter)&#xD;
&#xD;
        -  Medical treatment before and during the pregnancy&#xD;
&#xD;
        -  complications; occurrences during the pregnancy&#xD;
&#xD;
        -  Modalities of medical attention during delivery: mother/child Patient's data are coded,&#xD;
           and therefore anonymous, by using the inclusion number and initials of the patient&#xD;
           (first letter of name and first letter of surname (ex: 01-X_X).&#xD;
&#xD;
      In this prospective and retrospective, multi-centre, clinical study, all patients enrolled in&#xD;
      the cohort will be included in the statistical analysis. As an observational non-randomized&#xD;
      single arm evaluation, the statistical analyses will be descriptive. A minimum of 100&#xD;
      patients will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2, 2013</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>evaluate clinical characteristics</measure>
    <time_frame>Jan 2018</time_frame>
    <description>Purpose is to realise a French cohort of pregnancies in patients with dilated cardiomyopathy to evaluate clinical characteristics, study maternal and neonatal evolution and complications during pregnancy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>study maternal</measure>
    <time_frame>Jan 2018</time_frame>
    <description>Purpose is to realise a French cohort of pregnancies in patients with dilated cardiomyopathy to evaluate clinical characteristics, study maternal and neonatal evolution and complications during pregnancy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neonatal evolution</measure>
    <time_frame>Jan 2018</time_frame>
    <description>Purpose is to realise a French cohort of pregnancies in patients with dilated cardiomyopathy to evaluate clinical characteristics, study maternal and neonatal evolution and complications during pregnancy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>complications during pregnancy</measure>
    <time_frame>Jan 2018</time_frame>
    <description>Purpose is to realise a French cohort of pregnancies in patients with dilated cardiomyopathy to evaluate clinical characteristics, study maternal and neonatal evolution and complications during pregnancy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quarterly blood rate of Brain Natriuretic Peptide (BNP)</measure>
    <time_frame>Jan 2018</time_frame>
    <description>Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quarterly blood rate of N-Terminal pro-Brain Natriuretic Peptide (NTproBNP)</measure>
    <time_frame>Jan 2018</time_frame>
    <description>Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quarterly evolution of left ventricular ejection fraction</measure>
    <time_frame>Jan 2018</time_frame>
    <description>Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular ejection diameter</measure>
    <time_frame>Jan 2018</time_frame>
    <description>Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment before and during the pregnancy</measure>
    <time_frame>Jan 2018</time_frame>
    <description>Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modalities of medical attention during delivery</measure>
    <time_frame>Jan 2018</time_frame>
    <description>Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modalities of mother medical attention during peripartum</measure>
    <time_frame>Jan 2018</time_frame>
    <description>Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modalities of new-born medical attention</measure>
    <time_frame>Jan 2018</time_frame>
    <description>Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention</description>
  </secondary_outcome>
  <enrollment type="Actual">42</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>routinely care- no intervention</intervention_name>
    <description>routinely care- no intervention</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        pregnant women with dilated cardiomyopathy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over the age of majority&#xD;
&#xD;
          -  Followed-up for non-ischemic left heart failure, diagnosed before or during the&#xD;
             pregnancy or with peripartum history, with a left ventricular ejection fraction &lt; 50%&#xD;
             and/or a left ventricle diameter &gt; 27 mm/m2&#xD;
&#xD;
          -  In New York Heart Association (NYHA) class 1 to 4&#xD;
&#xD;
          -  Pregnant or with pregnancy history&#xD;
&#xD;
          -  Patients with left ventricular non-compaction, valvular cardiomyopathy operated or not&#xD;
             can also be enrolled&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal for participation&#xD;
&#xD;
          -  Ischemic, hypertrophic, restrictive and congenital cardiomyopathies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jean-Noel TROCHU, pu-ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NANTES</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU NICE</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hegp Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ap-Hp Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2017</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dilated cardiomyopathy</keyword>
  <keyword>registry</keyword>
  <keyword>heart failure</keyword>
  <keyword>pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03235063
org study id: Prog/10/17
nct id: NCT03235063
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Increasing cases of women with dilated cardiomyopathy with a project of pregnancy are
      observed. However there is few knowledge and publications about cardiac diseases in pregnant
      women. Moreover the majority of medical articles deal with women with congenital heart
      diseases, valvular pathologies or peripartum cardiomyopathies, and few data are available in
      literature about women with dilated cardiomyopathy diagnosed before or during the first
      months of the pregnancy.

      Cardiologist and obstetrician advices are considerably limited when patients with dilated
      cardiomyopathy have a pregnancy project. Knowledges and know-how are currently based on
      limited personal experiment or on few clinical cases descriptions.

      Pregnancy represents a high-risk situation for patients with dilated cardiomyopathy. Creation
      of a cohort of pregnant women with dilated cardiomyopathy collecting specific data will allow
      to have a better overview and to appreciate possibilities of a pregnancy project, evolution
      risks and modalities for medical attention and to improve follow-up and advices delivered to
      these patients.
This study is a national (20 centres) retrospective (10 years) and prospective registry of
      pregnant women with dilated cardiomyopathy.

      As this study is observational, medical attention of the enrolled patients will not be
      modified. No specific visit is planned for the study.

      Before the enrolment of the patient, the investigator provides the subject with clear and
      precise information about the protocol and requests her for written informed consent. The
      French ethical committee gave the investigators the possibility to include women in the
      registry if the investigators are unable to inform her (deceased women, no follow-up).

      The main objective of the study is to evaluate clinical characteristics and study maternal
      and neonatal evolution and complications during pregnancy using analysis of the
      morbi-mortality and clinical and para clinical criteria.

      The following data will be compiled in a case report form (e-CRF):

        -  Risk factors, cardiac history

        -  BNP or NTproBNP value, echocardiographic data (LVEF and LV diameter)

        -  Medical treatment before and during the pregnancy

        -  complications; occurrences during the pregnancy

        -  Modalities of medical attention during delivery: mother/child Patient's data are coded,
           and therefore anonymous, by using the inclusion number and initials of the patient
           (first letter of name and first letter of surname (ex: 01-X_X).

      In this prospective and retrospective, multi-centre, clinical study, all patients enrolled in
      the cohort will be included in the statistical analysis. As an observational non-randomized
      single arm evaluation, the statistical analyses will be descriptive. A minimum of 100
      patients will be enrolled.
observational model: Cohort
time perspective: Prospective
measure: evaluate clinical characteristics
time frame: Jan 2018
description: Purpose is to realise a French cohort of pregnancies in patients with dilated cardiomyopathy to evaluate clinical characteristics, study maternal and neonatal evolution and complications during pregnancy.
measure: study maternal
time frame: Jan 2018
description: Purpose is to realise a French cohort of pregnancies in patients with dilated cardiomyopathy to evaluate clinical characteristics, study maternal and neonatal evolution and complications during pregnancy.
measure: neonatal evolution
time frame: Jan 2018
description: Purpose is to realise a French cohort of pregnancies in patients with dilated cardiomyopathy to evaluate clinical characteristics, study maternal and neonatal evolution and complications during pregnancy.
measure: complications during pregnancy
time frame: Jan 2018
description: Purpose is to realise a French cohort of pregnancies in patients with dilated cardiomyopathy to evaluate clinical characteristics, study maternal and neonatal evolution and complications during pregnancy.
measure: quarterly blood rate of Brain Natriuretic Peptide (BNP)
time frame: Jan 2018
description: Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention
measure: quarterly blood rate of N-Terminal pro-Brain Natriuretic Peptide (NTproBNP)
time frame: Jan 2018
description: Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention
measure: quarterly evolution of left ventricular ejection fraction
time frame: Jan 2018
description: Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention
measure: left ventricular ejection diameter
time frame: Jan 2018
description: Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention
measure: treatment before and during the pregnancy
time frame: Jan 2018
description: Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention
measure: modalities of medical attention during delivery
time frame: Jan 2018
description: Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention
measure: modalities of mother medical attention during peripartum
time frame: Jan 2018
description: Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention
measure: modalities of new-born medical attention
time frame: Jan 2018
description: Analyse specific data of the pregnancy follow-up such as quarterly blood rate of Brain Natriuretic Peptide (BNP) or N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) and cardiac echography for quarterly evolution of left ventricular ejection fraction and diameter measurement Analyse treatment before and during the pregnancy Analyse modalities of medical attention during delivery Analyse modalities of mother medical attention during peripartum Analyse modalities of new-born medical attention
intervention type: Other
intervention name: routinely care- no intervention
description: routinely care- no intervention
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: Female
minimum age: 18 Years
maximum age: N/A
last name: Jean-Noel TROCHU, pu-ph
role: Principal Investigator
affiliation: CHU de Nantes
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: France
responsible party type: Sponsor
mesh term: Cardiomyopathies
mesh term: Cardiomyopathy, Dilated